InstaRX Review
Best for: Patients in any of the 50 states or DC seeking a multi-product compounded-medication telehealth platform (GLP-1 + peptides + sexual health) where they prefer to complete an intake to see pricing rather than comparing public per-dose tiers. NOT recommended for patients who require transparent upfront pricing, named pharmacy-partner disclosure, or visible LegitScript/HIPAA accreditation before committing to an intake.
InstaRX (instarx.com) is a multi-product compounded-medication telehealth platform operated by Insta RX, LLC (Huntington Beach, CA) that offers compounded GLP-1 injections (semaglutide, tirzepatide), anti-aging peptides (NAD+, Sermorelin, B12/MIC), and sexual-health medications (sildenafil, tadalafil). The clinical entity behind InstaRX is Dr Telx (drtelx.com), an independent third-party medical practice whose physicians are licensed across all 50 states and DC. The public-facing pricing is opaque: the only price quoted on the home page is the 'Get Started For Just $199' marketing hook, with no per-dose, monthly, or subscription pricing disclosed publicly without completing an intake. No LegitScript badge, HIPAA seal, or named compounding-pharmacy partner is shown on public pages.
Medium confidence · Last verified 2026-05-15 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
InstaRX is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
InstaRX prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Get Started intake offer | compounded | $199 |
| Get Started intake offer | compounded | $199 |
✓ Pros
- •All 50 states + DC coverage (per public FAQ: 'InstaRX is available in all 50 states and the District of Columbia')
- •Multi-product platform — patients can manage GLP-1 + anti-aging peptides + sexual-health medications on one account
- •Compounded semaglutide AND compounded tirzepatide both offered
- •Independent third-party provider group (Dr Telx) is named in the Terms of Service — partial transparency
✗ Cons
- •No per-dose, monthly, or subscription pricing disclosed publicly — only 'Get Started For Just $199' marketing hook; patients cannot compare costs without completing an intake
- •No LegitScript badge, HIPAA seal, or NABP accreditation displayed on public-facing pages
- •No compounding-pharmacy partner named on public-facing pages (the site only states 'compounded GLP-1s exclusively from U.S. pharmacies')
- •Terms of Service is generic boilerplate (the language 'consultations limited to diagnosis and treatment of certain women's health issues' appears to be a copy-paste error from a women's health platform — suggests low template hygiene)
- •Delaware governing law for arbitration disputes — typical telehealth platform structure but offers no California consumer protections despite the Huntington Beach corporate address
- •Corporate address is a strip-mall suite (15061 Springdale St. Suite 206, Huntington Beach, CA) — suggests pure-virtual operation without clinical or pharmacy infrastructure on-site
Ready to start with InstaRX?
Starting at $199/month. See current pricing and start your free consultation.
Sources & methodology
Our InstaRX review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to InstaRX
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with InstaRX?
Starting at $199/month. See current pricing and start your free consultation.